Today, Ruike Bio will be officially listed on the Hong Kong Stock Exchange!

According to the recent announcement of Ruike Bio, the company will be officially listed on the Hong Kong Stock Exchange today (March 31)
.

Recco Bio is an innovative vaccine company.

The core product, REC603, is a 9-valent recombinant human papillomavirus (HPV) vaccine for the prevention of cervical cancer, which is in phase 3 clinical trials

Screenshot source: Reference [1]

Founded in 2012, Ruike Bio is committed to the development and commercialization of subunit vaccines.
The company's core scientific team has more than 20 years of experience in the development and commercialization of innovative vaccines
.

Driven by new adjuvant technology, protein engineering technology, and immune evaluation technology, Ruike Bio has established a product pipeline including 12 innovative vaccines under development, covering cervical cancer, new coronary pneumonia, tuberculosis, herpes zoster, hand, foot and mouth sickness and influenza

A product pipeline of 12 innovative vaccines under development has been established, covering diseases such as cervical cancer, new coronary pneumonia, tuberculosis, herpes zoster, hand, foot and mouth disease and influenza

According to the prospectus, Ruike Biotech has previously completed multiple rounds of financing.
Investors include Qingchi Capital, Temasek, Legend Capital, Zhouling Capital, Dongfang Fuhai, Woying Investment, Sequoia Hanchen, CMB International, Zhiming Haojin , Meinian Health,
etc.

In this IPO, Ruike Bio also introduced 4 cornerstone investors , namely Yangtze River Hong Kong, Harvest, SCHP and Sequoia Capital China Growth

Ruike Bio also introduced 4 cornerstone investors

HPV vaccine pipeline

HPV vaccine pipeline

HPV is a common reproductive tract viral pathogen
.

Although HPV infection may clear without any intervention within a few months, several types of HPV persist and develop into cervical cancer

REC603 , the core product of Ruike Bio, is a recombinant HPV nine-valent vaccine candidate designed to provide protection against HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58
.

In the phase 1 clinical trials that have been carried out, the vaccine candidate has shown good immunogenicity and safety

The core product, REC603, is a recombinant HPV nine-valent vaccine candidate.

The second- generation recombinant HPV quadrivalent vaccine The second- generation recombinant HPV nine-valent vaccine is based on a new type of adjuvant, and this new type of vaccine may use a two-shot dosing regimen

▲ Ruike biological product pipeline (source of screenshot: Reference [1])

▲ Ruike biological product pipeline (source of screenshot: Reference [1])

COVID-19 vaccine and others

COVID-19 vaccine and others

In addition to the HPV vaccine, there is a new coronary pneumonia vaccine that is progressing faster in the Rico Bio product pipeline
.

Among them, the recombinant new coronary pneumonia vaccine ReCOV adopts the NTD-RBD-foldon protein structure and targets NTD and RBD , which are the main immunodominant regions on the spike protein, which is responsible for mediating SARS- CoV-2 enters cells expressing angiotensin-converting enzyme 2

The recombinant new coronary pneumonia vaccine ReCOV adopts the NTD-RBD-foldon protein structure and targets NTD and RBD

In addition, Ruike Bio has a number of candidate vaccines against other diseases in its product pipeline, including: REC610, a recombinant shingles vaccine, currently in the IND filing stage; REC607 and REC606, two adult tuberculosis vaccines; REC617, A recombinant quadrivalent influenza vaccine; REC605, a recombinant quadrivalent vaccine for hand, foot and mouth disease

According to the prospectus, the funds raised by Ruike Bio will be mainly used for the research and development and commercialization of the HPV vaccine pipeline, as well as the new coronary pneumonia vaccine, recombinant herpes zoster vaccine, tuberculosis vaccine, recombinant influenza quadrivalent vaccine, and hand, foot and mouth disease quadrivalent vaccine.

References:

References:

[1] Prospectus of Ruike Bio.

[1] Prospectus of Ruike Bio.
Retrieved Mar 30, 2022, from https://www1.
hkexnews.
hk/listedco/listconews/sehk/2022/0321/2022032100026_c.
pdf

[2] Recbio official website.
From https:// Recbio official website.
From https://